New hope for the 70% of cancer patients who fail checkpoint therapy. Our first-in-class lead from our IO platform will advance to IND in 2027 and to the clinic in 2028 pending Agency approval.
This company has no org chart yet
This company has no teams yet
This company has no offices yet